Not provided
Not provided
Not provided
Not provided
Not provided
Problem with enrollment due to Covid-19
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm
Prospective, single-arm, multi-center, all-comers registry with clinical follow-up visits at the hospital or by phone at 6 and 12 months post-procedure. A minimum of 1000 patients will be enrolled in approximately 15 sites in Brazil, including at least 415 patients with reference vessel diameter ≤2.75 mm as assessed by online QCA.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Orsiro Sirolimus Eluting Coronary Stent System | Device | Percutaneous coronary intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Target Lesion Failure for the small vessel group | Primary endpoint will be Target Lesion Failure (TLF) at 12 months for the small vessels group, defined as a composite of cardiac death, target vessel Myocardial Infarction (MI) or clinically driven Target Lesion Revascularization (TLR) | at 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| TLF for the overall cohort | TLF at 12 months post procedure for the overall cohort | at 12 months |
| Clinically driven Target Lesion Revascularization (TLR) | Clinically driven Target Lesion Revascularization (TLR) at 6 and 12 months post procedure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pregnant and/or breast feeding females at the time of enrolment
Known allergies to Acetylsalicylic Acid (ASA), clopidogrel, ticlopidin, heparin or any other anticoagulant
/antiplatelet required for PCI, contrast medium, sirolimus, or similar drugs, or the stent materials that cannot be adequately pre-medicated
Currently participating in another study that has not yet reached the primary endpoint
Not provided
Not provided
Not provided
This registry will include subjects requiring a treatment of coronary artery disease with an Orsiro DES
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pedro Braga, MD | Centro Hospitalar de Vila Nova de Gaia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de Santa Cruz | Carnaxide | 2799-134 | Portugal | |||
| Hospital da Luz |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| at 6 and 12 months |
| Clinically driven Target Vessel Revascularization (TVR) | Clinically driven Target Vessel Revascularization (TVR) at 6 and 12 months post procedure | at 6 and 12 months |
| Definite and probable stent thrombosis | Definite and probable stent thrombosis at 6 and 12 months post procedure (ARC Definition) | at 6 and 12 months |
| Procedure success | defined as achievement of a final diameter stenosis of <30% by investigator's visual estimate (using any percutaneous method) without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay | 12 months |
| Device success | defined as a final residual diameter stenosis of <30% by investigator's visual estimate, using the assigned device only, successful delivery of the stent to the target lesion site in the coronary artery, appropriate stent deployment, and successful removal of the device. Post-dilatation is allowed to achieve device success | 12 months |
| Carnaxide |
| Portugal |
| Hospital Espirito Santo Evora | Evora | Portugal |
| Centro Hospitaler de Leiria E.P.E. | Leiria | 2410-197 | Portugal |